Central aortic pressure and long-term outcome in hypertensive patients undergoing percutaneous coronary intervention

Han-Ping Wu1,2,3 & Mao-Jen Lin4,5

Elevated central pulse pressure (CPP) had a negative influence on long-term outcome in patients with hypertension (HT). However, little is known about the impact of central pulse pressure on long-term outcomes in hypertensive patients undergoing PCI. A total number of 1184 hypertensive patients who received PCI procedure were prospectively collected. They were divided into two groups according to the median of central pulse pressure. Baseline characteristics, risk factors, hemodynamic data including central systolic pressure (CSP), central diastolic pressure (CDP) and CPP were measured. Invasive strategies were also analyzed to compare the long term outcome between patients with reference CPP and patients with high CPP. We further analyzed the predictors for myocardial infarction (MI), mortality, repeated PCI procedure in hypertensive patients undergoing PCI. We found patients in the reference CPP group had a lower CSP and higher CDP compared with high CPP group (Both P < 0.001) and male preponderance (P < 0.001). Patients with diabetes and chronic kidney disease (CKD) tend to have a high CPP (both P < 0.001). Drugs including Angiotensin Converting Enzyme inhibitors (ACEI) and statin were used more frequently in patients with reference CPP group (P = 0.035 and P = 0.001, respectively). Freedom from all-cause mortality and cardiovascular (CV) mortality was lower in the patients with high CPP group (P = 0.001, P = 0.01, respectively). Logistic regression revealed that CPP is a major predictor for all-cause mortality and repeated PCI procedure [hazard ratio (HR): 2.46 and 1.41, respectively]. In hypertensive patients receiving PCI, elevated CPP had a negative impact on long-term mortality; CPP also strongly predicts all-cause mortality and repeated PCI procedures in hypertensive patients undergoing PCI.

Percutaneous coronary intervention (PCI) is a common therapeutic strategy in patients with coronary artery disease (CAD). Atherosclerotic plaque can be treated via different techniques such as expansion of the lumen by stretching and tearing the plaque (eg, balloon angioplasty), scaffolding the plaque (eg, coronary stents), removing the plaque (eg, atherectomy), or ablating the plaque (eg, laser angioplasty). However, even with introduction of modern techniques, adverse events still occurred in a high proportion of patients after receiving PCI. Major adverse cardiovascular event (MACE) of patients undergoing PCI include myocardial infarction (MI), revascularization and death1. Major risk factors for developing CAD including diabetes mellitus (DM), hypertension, dyslipidemia, and chronic kidney disease could also affect outcomes in CAD patients receiving PCI2–4.

Central pulse pressure (CPP) is equal to central systolic pressure minus central diastolic pressure. Recently, CPP has been proved to strongly associated with cardiovascular outcome and might serve as a better predictor than brachial pressure5–12 in patients with hypertension. For patients undergoing repeated PCI, CPP was also strongly related with MI attack, CV mortality, and all-cause mortality13. Nevertheless, there is no study thus far...
as for central aortic pressure and long-term outcome focusing on hypertensive patients undergoing PCI. Therefore, in this study, we aimed to evaluate the role of CPP in hypertensive patients receiving PCI, and compare the long-term outcome between patients with reference CPP or high CPP value. We further analyzed the major predictors for myocardial infarction (MI), repeated PCI and mortality in hypertensive patients undergoing PCI.

Methods and materials

Study population. The study was a clinical cohort based on prospective design and conducted via medical record and catheterization data review from 2007 through 2018. We consecutively recruited hypertensive patients undergoing PCI patients aged between 20 and 90 years from the inpatient clinic at Taichung Tzu Chi Hospital, Taiwan. According to median of CPP, they were divided into two groups: hypertensive patients with reference CPP (CPP equal to or less than median); hypertensive patients with high CPP (CPP more than median). Patients with the following conditions: scheduled PCI, end-stage heart failure, underlying malignancy, and occurrence of major adverse cardiovascular event (MACE) within 30 days after undergoing PCI were all excluded. The primary end-points include myocardial infarction, cardiovascular mortality, all-cause mortality and repeated PCI. Most patients were followed up regularly via the outpatient department (OPD) basis. For very few patients lost follow-up at OPD, usually a telephone call would be used to contact the patients themselves or their families. The Institution Review Board and ethics committee of Taichung Tzu Chi Hospital approved the study protocol. This cohort study also fulfilled the guidance of Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.

Data processing, measurements and analysis. Comparisons of baseline characteristics, hemodynamic data on cardiac catheterization, major risk factors and differences between treatment strategies such as drug medications after PCI or invasive procedures (balloon angioplasty, bare metal stent deployment or drug-eluting stent deployment) were all gathered in our study. The measurements of body habitus included body height, body weight, and body mass index (BMI). Baseline biochemical data including fasting plasma glucose, creatinine, total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), serum triglyceride and creatinine level during index PCI were all collected. HT is defined as a usual BP of 140/90 mm Hg or higher, BP levels for which the benefits of pharmacologic treatment have been definitely established. Diabetes was defined as a fasting plasma glucose level of more than 126 mg/dL, a casual plasma glucose level greater than 200 mg/dL or a hemoglobin A1c (HbA1c) level of more than 6.5%. Hypocholesterolemia was defined as a serum cholesterol level of more than 200 mg/dL or an LDL-C level of more than 100 mg/dL. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m², which is equal to or more than stage III chronic kidney disease (CKD). Previous MI history was defined as a history of MI prior to first-time PCI, accompanied by a threefold elevation of cardiac enzymes from the baseline value. Before coronary angiography, a cocktail including nitroglycerine 300 µg, verapamil 5 mg and heparin 5000 units were injected into radial artery after successful puncture. The central aortic pressure (CAP) was measured via a pigtail catheter while performing a coronary angiography. As for the hemodynamic data, CAP including CSP, CDP, and CPP were measured continuously and mean value were calculated during the whole time of catheterization. Angiographic findings, including the number of diseased vessels and lesion locations were calculated and lesion severity and complexity were evaluated via the synergy between PCI with Taxus Express paclitaxel-eluting stent (Boston Scientific, Marlborough, MA, USA) and cardiac surgery score (SYNTAX score). Related clinical parameters including baseline characteristics, hemodynamic data, related risk factors and invasive strategies were compared between patients with reference group and high CPP group. In addition, we intended to identify the significant predictors for major adverse outcomes including myocardial infarction (MI), all-cause mortality, CV mortality and repeated PCI procedures.

Statistical analysis. The analysis was primarily used to compare the differences between the two groups. Analysis of variance (ANOVA) was used to test continuous variables. Pearson’s chi-squared test, Fisher’s exact test was used to examine categorical variables. The log-rank test and Kaplan–Meier curves were used for the survival analysis. The Cox proportional hazards model was used to test the effect of independent variables on hazards. P values less than 0.05 were considered significant. All analyses were performed by using the statistical package SPSS for Windows, Version 23.0 (IBM Corp., Armonk, NY, USA).

Ethics approval and consent to participate. The study protocol was approved by the Institution Review Board and ethics committee of Taichung Tzu Chi Hospital, Taiwan (REC108-12), and written informed consent was obtained from all study participants.

Results

During the study period, a total of 1184 hypertensive patients who underwent PCI procedure were collected. The median of CPP according to cardiac catheterization is 66 mmHg. Based on the median of CPP, 1184 patients were divided into two groups. 601 patients and 583 patients were classified into reference CPP and high CPP group, respectively. The mean follow-up time for low CPP and high CPP group was 227.5 ± 135 weeks versus 229.2 ± 133.0 weeks, respectively (P = 0.823).

The baseline clinical characteristics were listed in Table 1. Patients with high CPP group were older than that with reference CPP group (69.2 ± 10.8 vs. 62.4 ± 12.4 years old, P < 0.001). They also had a higher serum creatinine level (2.3 ± 2.7 mg vs 1.6 ± 2.0 mg, P < 0.001). As for the body habitus parameters, patients in the high CPP group had a lower body mass index (BMI) than patients in the reference CPP group (P = 0.003). Given
and a lower CDP (72.9 ± 12.4 vs. 75.7 ± 14.0 mmHg) than those with reference CPP group (P < 0.001; P = 0.006, respectively). Therefore, we think it is an important issue to control CPP tightly in order to achieve a better outcome in hypertensive patients with end-stage renal disease, central pressure had a more predictive value for MACE than did brachial artery pressure19. In another study for hypertensive patients with poor control group; in other words, hypertensive patients with poor control might have more advanced arterial stiffness and atherosclerosis than those with good control. In our study, we found patients in the reference group used more ACEI inhibitors and statin but less calcium channel blockers (CCB) compared to those in the with high CPP group (P = 0.035, P = 0.001, P = 0.001, respectively). The results of angiographic findings and clinical outcomes are shown in Table 3. There is no difference as for the distribution of diseased vessels between both group; however, patients with high CPP tend to have more treated lesions (P = 0.044). They also received more balloon angioplasty (P = 0.013) but fewer drug eluting stent (DES) deployment (P = 0.046). Patients with high CPP group had a higher rate of all-cause mortality and CV mortality than reference CPP group (P = 0.002, P = 0.01, respectively). However, there was no difference in terms of MI or repeated PCI procedure (P = 0.678, P = 0.399, respectively). Figure 1 revealed the cumulated rate of freedom from MI, CV death, all-cause death and repeated PCI procedures between the two groups. Freedom from all-cause death and CV death was lower in the high CPP group (P = 0.002, P = 0.01, respectively).

The related factors in predicting the MACE are shown in Table 4. Multivariate regression was used for analysis. Based on the results of Cox regression model, we found that high CPP, advanced age, previous MI would increase the risk of all-cause mortality, whereas usage of statins and preserved left ventricular ejection fraction (LVEF) would reduce the risk. Advanced age and previous MI would increase the risk of CV mortality, however; usage of CCB and preserved LVEF would reduce the risk, Finally, high CPP, male gender, presence of CKD and more treated lesions during index PCI would increase the risk of repeated PCI procedures; on the other hand, usage of statins and preserved LVEF would reduce the risk of repeated PCI procedures.

**Discussion**

It has been well established that central pressure is a more accurate predictor for vascular disease and outcome than brachial pressure. However, the impact of central pressure on long-term outcomes in hypertensive patients with CAD undergoing PCI remains obscure. In the current study, we found that in hypertensive patients receiving PCI, high CPP had a negative impact on long-term all-cause mortality and CV mortality; high CPP also strongly predicts all-cause mortality and repeated PCI procedures in hypertensive patients undergoing PCI. In our study, we found a high CPP was a strong factor for patients undergoing PCI procedure. As shown in methodology in CAFÉ study, the CPP was calculated via indirect measurement through radial artery applanation tonometry and pulse wave analysis was also recorded; whereas in our study the CPP was continuously measured and the mean value was calculated during the whole catheterization time via a pigtail catheter, this may have more exactly reflected the true central pressure and vessel wall stress than that in CAFÉ study. In current study, hypertensive patients with poor control group also had a higher CPP and a lower CDP than that in hypertensive patients with good control group; in other words, hypertensive patients with poor control might have more advanced arterial stiffness and atherosclerosis than those with good control. In another study for patients with end-stage renal disease, central pressure had a more predictive value for MACE than did brachial artery pressure19. Therefore, we think it is an important issue to control CPP tightly in order to achieve a better outcome in hypertensive patients undergoing PCI.

In hypertensive patients with high CPP, they have a preponderance for aged people, female patients, patient with CKD or diabetes. In aged people group, it also have a high percentage of isolated systolic hypertension (ISH), high CPP will be measured and might thus confound the result. These patients also have a poor control of blood pressure even though they need more strict blood pressure control. On the other hand, aged and female hypertensive patients, hypertensive patient with CKD or DM are also at high risk for advanced atherosclerosis.

**Table 1.** General characteristic of study population. BMI: body mass index, CSP: central systolic pressure, CDP: central diastolic pressure, CPP: central pulse pressure, HDL: high-density lipoprotein cholesterol, LDL: low-density lipoprotein cholesterol, TG: triglyceride. *Significant.

| Variable | Reference CPP (N = 601) | High CPP (N = 583) | P value |
|----------|------------------------|-------------------|---------|
| Age (years) | 62.4 ± 12.4 | 69.2 ± 10.8 | < 0.001* |
| Weight (kg) | 71.3 ± 13.3 | 65.7 ± 12.2 | < 0.001* |
| Height (m) | 1.64 ± 0.08 | 1.60 ± 0.08 | < 0.001* |
| BMI (kg/m2) | 26.4 ± 4.3 | 25.7 ± 4.3 | < 0.001* |
| CSP (mmHg) | 127.2 ± 16.4 | 158.7 ± 19.0 | < 0.001* |
| CDP (mmHg) | 75.7 ± 14.0 | 72.9 ± 12.4 | < 0.001* |
| CPP (mmHg) | 51.5 ± 9.7 | 85.8 ± 16.0 | < 0.001* |
| Cholesterol (mg/dL) | 175.8 ± 44.2 | 176.3 ± 43.7 | 0.844 |
| HDL (mg/dL) | 38.2 ± 15.3 | 39.6 ± 17.2 | 0.141 |
| TG (mg/dL) | 156.0 ± 106.4 | 158.7 ± 104.0 | 0.666 |
| LDL (mg/dL) | 106.3 ± 38.2 | 104.9 ± 37.5 | 0.536 |
| Serum creatinine (mg/dL) | 1.6 ± 2.0 | 2.3 ± 2.7 | < 0.001* |
### Table 2. Demography and clinical data of study population and medications prescribed after index PCI.

Previous MI: history of previous myocardial infarction, CABG: history of coronary artery bypass graft, CKD: chronic kidney disease, P2Y12 inhibitor: P2Y12 receptor inhibitor of platelet, BB: beta-blockers, CCB: calcium channel blocker, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker. P value for Pearson’s chi-squared test or Fisher’s exact test. *Significant.

| Variable          | Reference CPP (% (N = 601)) | High CPP (% (N = 583)) | P value |
|-------------------|-----------------------------|------------------------|---------|
| **Gender**        |                             |                        |         |
| Female            | 110 (18.3)                  | 238 (40.8)             | <0.001* |
| Male              | 491 (81.7)                  | 345 (59.2)             |         |
| **Dyslipidemia**  |                             |                        | 0.460   |
| No                | 284 (47.3)                  | 288 (49.4)             |         |
| Yes               | 317 (52.7)                  | 295 (50.6)             |         |
| **DM history**    |                             |                        | <0.001* |
| No                | 363 (60.4)                  | 277 (47.5)             |         |
| Yes               | 238 (39.6)                  | 306 (52.5)             |         |
| **Current smoker**|                             |                        | <0.001* |
| No                | 330 (54.9)                  | 405 (69.5)             |         |
| Yes               | 271 (45.1)                  | 178 (30.5)             |         |
| **CKD**           |                             |                        | <0.001* |
| No                | 367 (61.1)                  | 226 (38.8)             |         |
| Yes               | 234 (38.9)                  | 357 (61.2)             |         |
| **Previous MI**   |                             |                        | <0.001* |
| No                | 383 (63.7)                  | 440 (75.5)             |         |
| Yes               | 218 (36.3)                  | 143 (24.5)             |         |
| **Stroke history**|                             |                        | 0.163   |
| No                | 565 (94.0)                  | 536 (91.9)             |         |
| Yes               | 36 (6.0)                    | 47 (8.1)               |         |
| **CABG history**  |                             |                        | 1.000   |
| No                | 596 (99.2)                  | 579 (99.3)             |         |
| Yes               | 5 (0.8)                     | 4 (0.7)                |         |
| **Aspirin**       |                             |                        | 0.905   |
| No                | 60 (10.0)                   | 57 (9.8)               |         |
| Yes               | 541 (90.0)                  | 526 (90.2)             |         |
| **P2Y12 inhibitor**|                             |                        | 0.171   |
| No                | 79 (13.1)                   | 93 (16.0)              |         |
| Yes               | 522 (86.9)                  | 490 (84.0)             |         |
| **Diuretics**     |                             |                        | 0.516   |
| No                | 468 (77.9)                  | 463 (79.4)             |         |
| Yes               | 133 (22.1)                  | 120 (20.6)             |         |
| **BB**            |                             |                        | 0.347   |
| No                | 298 (49.6)                  | 305 (52.3)             |         |
| Yes               | 303 (50.4)                  | 278 (47.7)             |         |
| **CCB**           |                             |                        | 0.001*  |
| No                | 398 (66.2)                  | 330 (56.6)             |         |
| Yes               | 203 (33.8)                  | 253 (43.4)             |         |
| **ACEI**          |                             |                        | 0.035*  |
| No                | 495 (82.4)                  | 506 (86.8)             |         |
| Yes               | 106 (17.6)                  | 77 (13.2)              |         |
| **ARB**           |                             |                        | 0.084   |
| No                | 386 (64.2)                  | 346 (59.3)             |         |
| Yes               | 215 (35.8)                  | 237 (40.7)             |         |
| **Statin**        |                             |                        | 0.001*  |
| No                | 320 (53.2)                  | 368 (63.1)             |         |
| Yes               | 281 (46.8)                  | 215 (36.9)             |         |
| **Fibrate**       |                             |                        | 0.730   |
| No                | 562 (93.5)                  | 548 (94.0)             |         |
| Yes               | 39 (6.5)                    | 35 (6.0)               |         |
and they may have a poor outcome even after undergoing PCI. In addition, calcium channel blockers (CCB) was used more frequently in the high CPP group, whereas ACEI and statins were used less frequently in high CPP group. It might imply that patients with higher CPP were older and had a high prevalence of ISH, therefore they used CCB more frequently. ACEI has been proved to effective in reducing cardiovascular event in stable CAD patients either with low or high risk. It is unclear why patients with reference CPP used ACEI and statin more frequently. Nevertheless, ARB seemed have less protective effect than ACEI in patients with diabetes or acute myocardial infarction (AMI) undergoing PCI from post-hoc analysis, whereas they also play a similar role in hypertensive patients is uncertain. On the other hand, both the serum TC or LDL-C value are in average level and there is no difference between two groups; however patients with reference CPP use statin more frequently and statin usage does reduce the hazard of all-cause mortality and repeated PCI from regression model. Currently, statin usage is recommended in all patient undergoing PCI even they have average cholesterol or LDL level.

| Variable                  | Reference CPP (%) (N = 601) | High CPP (%) (N = 583) | P value |
|---------------------------|-----------------------------|------------------------|---------|
| Follow-up time (weeks)    | 227.5 ± 135.0               | 229.2 ± 133.0          | 0.823   |
| Number of diseased vessels|                             |                        | 0.243   |
| Single-vessel disease     |                            |                        |         |
| Dual-vessel disease       |                            |                        |         |
| Triple-vessel disease     |                            |                        |         |
| Mean of treated vessels   | 1.2 ± 0.5                   | 1.3 ± 0.5              | 0.100   |
| Mean of treated lesions   | 1.5 ± 0.7                   | 1.6 ± 0.8              | 0.044*  |
| Type of intervention      |                             |                        |         |
| Balloon angioplasty       | 162 (27.0)                  | 196 (33.6)             | 0.013*  |
| BMS deployment            | 239 (39.8)                  | 258 (44.3)             | 0.118   |
| DES deployment            | 280 (46.6)                  | 238 (40.8)             | 0.046*  |
| SYNTAX score              | 11.3 ± 8.1                  | 10.3 ± 6.9             | 0.023*  |
| LVEF                      | 0.5 ± 0.1                   | 0.6 ± 0.1              | 0.014*  |
| MI                        |                             |                        | 0.678   |
| Yes                       | 20 (3.3)                    | 22 (3.8)               |         |
| No                        | 581 (96.7)                  | 561 (96.2)             |         |
| CV death                  |                             |                        | 0.010*  |
| Yes                       | 16 (2.7)                    | 33 (5.7)               |         |
| No                        | 585 (97.3)                  | 550 (94.3)             |         |
| All-cause death           |                             |                        | 0.002*  |
| Yes                       | 33 (5.5)                    | 60 (10.3)              |         |
| No                        | 568 (94.5)                  | 523 (89.7)             |         |
| Re-PCI                    |                             |                        | 0.399   |
| Yes                       | 158 (26.3)                  | 166 (28.5)             |         |
| No                        | 443 (73.7)                  | 417 (71.5)             |         |

Table 3. Demography of angiographic findings and clinical outcome. BMS: bare metal stent, DES: drug-eluting stent, SYNTAX score: Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score, LVEF: left ventricular ejection fraction, MI: myocardial infarction, Re-PCI: repeated percutaneous coronary intervention. *Significant.
Study limitation

First, the adherence to anti-hypertensive therapy was not surveyed in this study, which could have an influence on the long-term outcome. Second, data-entry bias might exist, functional evaluations of the atherosclerotic lesions by fraction flow reserve (FFR) or instantaneous wave-free ratio (IFR) measurement were not used in this study, which may also have an impact on the decision of index PCI. Third, the case numbers of MI and CV death are too few to yield statistical significance; we cannot exclude the possibility of inadequate follow-up time. Fourth, since most hypertensive patients receiving PCI in this study were aged people, this study may underpower the outcome of younger patients. Fifth, vasodilators and vasopressors had been used occasionally during PCI procedures in some conditions such as high or low blood pressure, coronary artery spasm and slow coronary flow, which might affect the mean CPP. Finally, since this is a observational study, whether aggressive lowering CPP could improve long-term outcome in hypertensive patients undergoing PCI remains obscure.

Conclusions

Elevated CPP during PCI in hypertensive patients carried a increased long-term mortality, and CPP may also serve as a predictor for all-cause mortality and repeated PCI procedures in hypertensive patients undergoing PCI.
Table 4. Significant predictors of outcome in Cox proportion hazard model for MI, all-death, CV-death, repeated PCI by using multivariate regression. CPP: central pulse pressure, BMI: body mass index, CKD: chronic kidney disease, MI history: previous history of myocardial infarction, BB: beta-blockers, CCB: calcium channel blocker, ACEI: angiotensin-converting enzyme inhibitor, DES: drug-eluting stent, SYNTAX score: Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score, LVEF: left ventricular ejection fraction. *Significant. a MI model: y = βdummyDH1 + βdummyDH2 + βdummyDH3 + βMI + βstroke + βstatin + βsyntax. b All-death model: y = βdummyDH1 + βdummyDH2 + βdummyDH3 + βage + βCKD + βMI + βstroke + βbetab + βstatin + βsyntax. c CV-death model: y = βdummyDH1 + βdummyDH2 + βdummyDH3 + βMI + βstroke + βdiuretics + βbetab + βsyntax. d Repeated PCI model: y = βdummyDH1 + βdummyDH2 + βdummyDH3 + βMI + βsmoking + βbetab + βsyntax.

Data availability
The data that support the findings of this study are available, on reasonable request, from the corresponding author.

Received: 25 March 2020; Accepted: 5 October 2020
Published online: 15 October 2020

References
1. Williams, D. O., Abbott, J. D., Kip, K. E. & DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation. 114, 2154–2162 (2006).
2. Lin, M. J., Chen, C. Y., Lin, H. D. & Wu, H. P. Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention. BMC Cardiovasc. Disord. 17, 12 (2017).
3. Mathew, V. et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of RESTenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 109, 476–480 (2004).
4. Lin, M. J., Lee, J., Chen, C. Y., Huang, C. C. & Wu, H. P. Chronic kidney disease and diabetes associated with long-term outcomes in patients receiving percutaneous coronary intervention. BMC Cardiovasc. Disord. 17, 242 (2017).
5. Laskey, W. K. et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am. J. Cardiol. 90, 1062–1067 (2002).
6. Saltzman, A. J. et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc. Interv. 4, 1011–1019 (2011).
7. Lin, M. J. et al. Hypertension and chronic kidney disease affect long-term outcomes in patients with stable coronary artery disease receiving percutaneous coronary intervention. Sci. Rep. 8, 17673 (2018).
8. Hannia, E. B. et al. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc. Interv. 4, 1002–1008 (2011).
9. Williams, B. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 113, 1213–1225 (2006).
10. Roman, M. J. et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: The Strong Heart Study. Hypertension 50, 197–203 (2007).
11. Rosenwasser, R. F. et al. Baseline predictors of central aortic blood pressure: A PEAR substudy. J. Am. Soc. Hypertens. 8, 152–158 (2014).
12. Vlachopoulos, C. et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: A systematic review and meta-analysis. Eur. Heart J. 15, 1865–1871 (2010).
13. Lin, M. J., Chen, C. Y., Lin, H. D., Lin, C. S. & Wu, H. P. Prognostic significance of central pulse pressure for mortality in patients with coronary artery disease receiving repeated percutaneous coronary intervention. Medicine (Baltimore) 95, e3218 (2016).
14. Vandenbroucke, J. P. et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Ann. Intern. Med. 147, W163–194 (2007).
15. Chobanian, A. V. et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 289, 2560–2572 (2003).
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl 1), S67–74 (2013).
17. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42, S1–201 (2003).
18. Serruys, P. W. et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360, 961–972 (2009).
19. London, G. et al. Increased systolic pressure in chronic uremia. Role of arterial wave reflections. Hypertension 20, 10–19 (1992).
20. Fox, K. M. & EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 362, 782–788 (2003).
21. Heart Outcomes Prevention Evaluation Study Investigators et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145–153 (2000).
22. Cheng, J. et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: A meta-analysis. JAMA Intern. Med. 174, 773–785 (2014).
23. Ann, S. H. et al. Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention. Int. J. Cardiol. https://doi.org/10.1016/j.ijcard.2019.11.086 (2019).

Acknowledgements
The authors wish to thank Hsun-Yang Chuang (MS), Taiwan centers for disease control, Taipei, Taiwan, for his assistance in statistical analysis.

Author contributions
M.J.L. and H.P.W. conceived and designed the study. All authors read and approved the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to M.-J.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020